Technical Analysis for VICL - Vical Incorporated

Grade Last Price % Change Price Change
grade A 1.23 1.65% 0.02
VICL closed up 1.65 percent on Friday, March 22, 2019, on 52 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical VICL trend table...

Date Alert Name Type % Chg
Mar 22 Crossed Above 200 DMA Bullish 0.00%
Mar 22 Stochastic Reached Overbought Strength 0.00%
Mar 22 Earnings Movers Other 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 22 Up 3 Days in a Row Strength 0.00%
Mar 21 200 DMA Resistance Bearish 1.65%
Mar 21 Earnings Movers Other 1.65%
Mar 20 Narrow Range Bar Range Contraction 3.36%
Mar 20 NR7 Range Contraction 3.36%
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup 6.03%

Older signals for VICL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its products include Allovectin, a Phase III clinical trial product to treat metastatic melanoma; CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex type 2 virus, which are under preclinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, develops TransVax, which is in Phase III clinical trial to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial to protect against CMV infection after solid organ transplants; Collategene, an angiogenic therapy encoding hepatocyte growth factor that is in Phase III clinical trials to induce local growth of blood vessels to restore blood flow to limbs affected by critical limb ischemia; Apex-IHN prophylactic vaccine for infectious hematopoietic necrosis virus, which is marketed for the prevention of infection and disease in farm-raised salmon when exposed to infected wild salmon in Canada; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. Vical Incorporated, through government collaboration, develops prophylactic and/or therapeutic HIV vaccine, a Phase IIb clinical trial product to prevent/treat infection, disease, and/or viral shedding; and Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. The company was founded in 1987 and is headquartered in San Diego, California.
Medicine Health Medical Specialties Diseases Disease Clinical Trial Infection Vaccination HIV Vaccines Clinical Trial Product Metastatic Melanoma Cancer Vaccine Biopharmaceutical Products Dengue Fever
Is VICL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.82
52 Week Low 0.85
Average Volume 416,587
200-Day Moving Average 1.2232
50-Day Moving Average 1.0364
20-Day Moving Average 1.127
10-Day Moving Average 1.185
Average True Range 0.0487
ADX 32.37
+DI 29.0185
-DI 11.5046
Chandelier Exit (Long, 3 ATRs ) 1.1039
Chandelier Exit (Short, 3 ATRs ) 1.1461
Upper Bollinger Band 1.2649
Lower Bollinger Band 0.9891
Percent B (%b) 0.87
BandWidth 24.47205
MACD Line 0.0471
MACD Signal Line 0.0402
MACD Histogram 0.0069
Fundamentals Value
Market Cap 14.03 Million
Num Shares 11.4 Million
EPS -1.04
Price-to-Earnings (P/E) Ratio -1.18
Price-to-Sales 2.02
Price-to-Book 0.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.30
Resistance 3 (R3) 1.30 1.27 1.29
Resistance 2 (R2) 1.27 1.26 1.27 1.28
Resistance 1 (R1) 1.25 1.25 1.26 1.25 1.28
Pivot Point 1.23 1.23 1.23 1.23 1.23
Support 1 (S1) 1.21 1.21 1.22 1.21 1.18
Support 2 (S2) 1.18 1.20 1.18 1.18
Support 3 (S3) 1.16 1.18 1.17
Support 4 (S4) 1.16